About Freenome
Freenome is a biotechnology company developing blood-based tests for early cancer detection using a multiomics platform and machine learning. Its proprietary AI-driven platform analyzes cell-free DNA, RNA, proteins, and other biomarkers from a routine blood draw to detect cancer at its earliest, most treatable stages. The company targets healthcare providers, health systems, and population health decision-makers, with its lead program focused on colorectal cancer screening.
Company details
Funding
Total raised
$1.4B
Last stage
Growth
Investors
Founders
Riley Ennis
Riley Ennis is Co-Founder and Chief Product Officer at Freenome Holdings, Inc.
Gabriel Otte
Co-founded Freenome in 2014 with a vision to use blood-based signals to detect cancer earlier. Led the company through its growth as CEO before departing.
LinkedInCharles Roberts
Co-founded Freenome in 2014 alongside Gabriel Otte and Riley Ennis.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.